Clinical Trials Logo

Staphylococcus Aureus clinical trials

View clinical trials related to Staphylococcus Aureus.

Filter by:

NCT ID: NCT00304811 Completed - Clinical trials for Staphylococcus Aureus

Vancomycin vs. Vancomycin Plus Gentamycin in Treatment of MRSA Infection

Start date: January 2006
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare the outcome of treatment for bacteremic MRSA infection with vancomycin alone, vancomycin plus gentamicin, vancomycin plus rifampin, and vancomycin plus gentamicin and rifampin.

NCT ID: NCT00254527 Completed - Clinical trials for Staphylococcus Aureus

Colonization, Infection, and Molecular Typing of Methicillin-Resistant Staphylococcus Aureus (MRSA) in Children.

Start date: January 2005
Phase: N/A
Study type: Observational

The intent of this study is to: 1. Define the prevalence of MRSA carriage in the pediatric population in Kansas City. 2. Systematically define patient risk factors for MRSA carriage and infection. 3. Characterize the unique genetic characteristics of MRSA strains, both community acquired (CA) and healthcare associated (HCA) that are present in the different pediatric populations.

NCT ID: NCT00198289 Completed - Clinical trials for Staphylococcus Aureus

Aurexis® in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs

Start date: April 2005
Phase: Phase 2
Study type: Interventional

Patients who are at least 7 years old with stable Cystic Fibrosis who have Staphylococcus aureus in their Lungs will be enrolled into the study and receive one dose of Aurexis® intravenously on Study Day 1, and will be followed until Study Day 57. Aurexis is a humanized monoclonal antibody that is designed to combat Staphylococcus aureus. The purpose of this study is to assess the safety and pharmacokinetic profile (concentration of Aurexis in blood and sputum) of Aurexis. Additionally, certain tests and measurements will be conducted to preliminarily determine if Aurexis demonstrates any benefit to these patients.